MedTrace Logo

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

NCT03109600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-06

No results posted yet for this study

Summary

This study is to assess the safety of Vi-DT vaccine in adults and children.

Conditions

  • Safety Issues

Interventions

BIOLOGICAL

Vi-DT (Bio Farma)

Typhoid Conjugate Vaccine

BIOLOGICAL

Vi polysaccharide vaccine

Vi polysaccharide vaccine

BIOLOGICAL

Influenzae vaccine

1 dose of Influenzae vaccine

BIOLOGICAL

Pneumococcal conjugate vaccine

1 dose of Pneumococcal conjugate Vaccine

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Bernie Endyarni, MD · Faculty of Medicine, University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-18
Primary Completion
2017-09-28
Completion
2018-02-19

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109600 on ClinicalTrials.gov